Skip to main content
H.R. 1405 119th Congress House

Enhancing Domestic Drug Manufacturing Competitiveness Act

Official title: To direct the Comptroller General of the United States to conduct a study to assess the key regulatory barriers that impede the expansion or siting of new phar… Show full official titleShow less

Official title: To direct the Comptroller General of the United States to conduct a study to assess the key regulatory barriers that impede the expansion or siting of new pharmaceutical manufacturing facilities in the United States, and for other purposes.

Introduced: February 18, 2025 Introduced by: Vern Buchanan Republican · Florida See on congress.gov
Health Administrative law and regulatory proceduresCongressional oversightEnvironmental regulatory proceduresGovernment studies and investigations
More subjectsShow fewer subjects
ManufacturingPrescription drugs
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 18, 2025
Referred to the House Committee on Energy and Commerce.
Feb 18, 2025
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now February 18, 2025

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

Enhancing Domestic Drug Manufacturing Competitiveness Act

This bill requires the Government Accountability Office (GAO) to study and report to Congress on key regulatory barriers to pharmaceutical manufacturing in the United States. 

Specifically, GAO must identify and assess, including by engaging stakeholders, barriers that impede expansion or siting of pharmaceutical manufacturing facilities in the United States or make the United States less competitive than other countries as a location for such facilities. GAO must consider (1) whether environmental or other regulations significantly delay and increase the cost of expanding or siting pharmaceutical manufacturing facilities in the United States; (2) the potential impact of environmental and other regulations on pharmaceutical supply chain resiliency; and (3) specific actions for regulators to address the identified barriers. 

Finally, the report must include recommendations for streamlining regulatory barriers and facilitating technological solutions to foster U.S. pharmaceutical manufacturing. 

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 1

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

 Cosponsors 1
All 1 Republican 1
R
Donalds, Byron
Florida · Feb 18, 2025
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1405: Enhancing Domestic Drug Manufacturing Competitiveness Act. 119th Congress. Open America. https://openamerica.io/bill/119-HR-1405/
MLA
"H.R. 1405: Enhancing Domestic Drug Manufacturing Competitiveness Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-1405/.
Bluebook (legal)
H.R. 1405, 119th Cong. (2026), https://openamerica.io/bill/119-HR-1405/.
Markdown link
[H.R. 1405: Enhancing Domestic Drug Manufacturing Competitiveness Act](https://openamerica.io/bill/119-HR-1405/)
Report a problem